KEEGO HARBOR, Mich., Feb. 01, 2018 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO), a biotech/agtech R&D company engaged in the commercialization of nutritional and medicinal products derived from proprietary algal strains, announces today the execution of a letter of intent to produce its proprietary algae strain at Tianjin Norland Biotech (Norland) facilities in China. Norland is one of the largest producers of algae in China, and is among the first growers to be signed by ZIVO to supply dried biomass for a range of applications. ZIVO anticipates that it will enter into a definitive, binding production agreement with Norland later in 2018.
The company is engaged in building a global supply chain to support anticipated demand for its algae-based feed, food and beverage ingredients. Over the past year, the company has been finalizing compliance and product formulation, positioning itself for a market introduction.
“The agreement in principle with Norland is a great start toward building global production capacity,” states Philip M. Rice, Chief Financial Officer. “We’re committed to developing a base of high-quality producers that will help us meet market objectives.”
About ZIVO Bioscience, Inc.
ZIVO Bioscience, Inc. (OTCQB:ZIVO) is a Michigan-based biotech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on autoimmune and inflammatory response modulation.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
Contact:
Investor Relations
(248) 452 9866 ext 150
ZIVO Bioscience, Inc.
Investor@zivobioscience.com